Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $5.95, but opened at $5.60. Valneva shares last traded at $5.60, with a volume of 5,504 shares trading hands.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research note on Wednesday, April 22nd. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday. Finally, Guggenheim set a $11.00 price objective on Valneva in a report on Thursday, April 16th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.98.

Valneva Stock Performance

The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The firm has a market cap of $527.59 million, a P/E ratio of -2.97 and a beta of 1.75. The business has a fifty day simple moving average of $6.02 and a 200-day simple moving average of $8.35.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $35.77 million during the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. On average, sell-side analysts predict that Valneva SE Sponsored ADR will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Valneva during the fourth quarter valued at approximately $44,000. Marex Group plc bought a new stake in shares of Valneva in the 2nd quarter worth approximately $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva in the 4th quarter worth approximately $94,000. VSM Wealth Advisory LLC increased its position in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Valneva during the 3rd quarter valued at approximately $124,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.